Lymphoma CAR-T cell immunotherapy treatment, new CAR-T cell therapy punches out, the effective rate is as high as 93%.
When it comes to relapsed / refractory mantle cell lymphoma, everyone may be a little strange. In fact, mantle cell lymphoma accounts for 6% of all non-Hodgkin’s lymphoma (NHL). The most common manifestation is lymphadenopathy, often accompanied by systemic symptoms. Based on the morphological findings and the tumor is a B-cell lymphoma, the hematological pathologist makes a correct diagnosis of mantle cell lymphoma. However, the mantle cell lymphoma CHOP (cyclophosphamide + doxorubicin + vincristine + prednisone) regimen is not satisfactory, and only a few patients have achieved complete remission.
However, just in the New England Journal on April 1, 2020, the MD Anderson Cancer Center published a new study on patients with relapsed / refractory mantle cell lymphoma. During the follow-up period, it was found that most patients with relapsed / refractory mantle cell lymphoma that are resistant to previous therapies may benefit from CD19-targeted chimeric antigen receptor (CAR) T cell (CAR-T) therapy.
The results of this study are particularly gratifying: 93% of the patients responded to CAR-T cell therapy KET-X19, while 67% of the patients had complete remission! During the median follow-up, 57% of the patients had complete remission and no progress is expected The survival period and overall survival period were 61% and 83%, respectively.
This is a multi-center, 20-site phase II ZUMA-2 study. The median age of 74 patients participating in this trial was 65 years, of which 84% were men. More than 80% of patients have stage IV disease, and more than 50% of patients have a moderate to high-risk prognosis after diagnosis of mantle cell lymphoma. All patients have experienced relapsed or refractory disease after receiving up to 5 therapies, and all have received Bruton’s tyrosine kinase (BTK) inhibitor therapy.
There are currently three approved BTK inhibitors, including ibrutinib, acalabrutinib, and zanubrutinib (Brukinsa), and the prognosis of patients with relapsed or refractory mantle cell lymphoma has been greatly improved after treatment with this drug, but accept this The prognosis of patients with disease deterioration after this treatment is very poor, with a median overall survival of only 6-10 months. At the same time, patients of this type are rarely eligible for allogeneic stem cell transplantation.
In CAR-T cell therapy, patients’ T cells are extracted through a process called leukapheresis, and after genetic modification, they express CAR molecules that help them attack cancer cells. These modified T cells are injected back into the patient. In this new study, a CAR-T cell therapy called KTE-X19 was discovered and applied to patients with relapsed / refractory mantle cell lymphoma.
Dr. Michael Wang, a professor of lymphoma and myeloma at the University of Texas MD Anderson Cancer Center, said: “ZUMA-2 is the first phase II multicenter study using CAR-T cells to treat relapsed / refractory mantle cell lymphoma, Its efficacy and safety results are encouraging. Although this study is continuing, the results we report (including controllable safety) indicate that this therapy is a good choice for patients with relapsed or refractory mantle cell lymphoma An effective and feasible treatment option. “
In addition, this study also reported side effects of grade 3 or higher, the most common being neutropenia and thrombocytopenia. Most patients experience cytokine release syndrome, which is a common side effect of CAR-T cell therapy, but this syndrome is effectively managed in all patients.
In addition to the above-mentioned breakthrough clinical research progress, major domestic hospitals are currently actively conducting CAR-T clinical studies of various tumors. If you want to participate in clinical trials, please consult the Global Oncology Network Medical Department for medical evaluation.
We firmly believe that after the introduction of a perfect cellular immune supervision system, the country will open the door to cellular immunotherapy to benefit more cancer patients, and our country’s cellular immunotherapy will also enter the international arena.
